Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-4774 + TDF in Untreated Chronic Hepatitis B
NCT02174276Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2014
- Primary completion
- Feb 2016
- Modality
- Viral Vector Vaccines, Therapeutic Vaccines
- Countries
- 6
01
Overview
A Phase 2 trial of GS-4774 in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Started Jul 2014; status: completed.
02
Drugs
GS-4774
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02174276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174276.